Angiotensin receptor blocker (any dose) Mean duration of 4 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Total mortality Mean duration of 3.8 years · adults 60 years or older with primary hypertension
Antihypertensive drug leads to lower total mortality Mean duration of 3.8 years compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cardiovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Cerebrovascular mortality + morbidity · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cerebrovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Coronary heart disease mortality + morbidity · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower coronary heart disease mortality and morbidity Mean duration of 2.9… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults 60 years or older with primary hypertension
Antihypertensive drug may leads to higher withdrawals due to adverse effects Mean duration of 4.6 years compared with placebo or no treatment (low certainty).
1 finding from 1 review
Beta‐blocker (any dose) Mean duration of 4 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Calcium channel blocker (any dose) Mean duration of 3 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Beta‐blocker/thiazide combination (any dose) Mean duration of 10 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
All‐cause mortality · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower total cardiovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Cerebrovascular mortality + morbidity · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower cerebrovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Coronary heart disease mortality + morbidity · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in coronary heart disease mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
It is very uncertain whether antihypertensive drug therapy changes withdrawal due to adverse events compared with control (very low certainty).
1 finding from 1 review
Decrease in SBP5 at end of 1 year · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
1 finding from 1 review
Decrease in DBP6 at end of 1 year · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
1 finding from 1 review